Linagliptin Sandoz (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which increase insulin secretion and decrease glucagon release in a glucose‑dependent manner, thereby lowering blood sugar.

The specific dose of Linagliptin Sandoz is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Linagliptin Sandoz, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its primarily non‑renal elimination, which means dose adjustment is generally not required in renal impairment, unlike some alternatives that require renal dose modifications.

Linagliptin Sandoz should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Linagliptin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and hypoglycaemia when used together with insulin or sulfonylureas. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling, or signs of an allergic reaction.

Linagliptin should be avoided in patients with a known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with a history of pancreatitis, severe hepatic impairment, or those who are pregnant or breastfeeding unless the prescriber determines the benefits outweigh the risks.